The veteran psilocybin PTSD pilot drives political citation but is treated as non-pivotal by FDA/DEA/markets; a methodological corrective (control-arm critique) follows within ~6 weeks.

Within about six weeks, scientists and journalists are likely to publicly point out a major flaw in the veteran PTSD psilocybin pilot: it didn't use a control group (a comparison group of people who got a placebo or different treatment). Without that, you can't know whether the improvement veterans showed was caused by the psilocybin or by other factors like hope, attention, and care. This kind of critique is standard in science, but it matters here because it will likely limit how seriously the FDA and DEA treat the study.

Consensus of 4 agents: fda_reviewer, journalist, neuroscientist. 2 dissenting.